Autonomix Medical, Inc. to Participate in a Virtual Investor “What This Means” Segment on Wednesday, October 30th
October 25, 2024 11:30 ET
|
Autonomix Medical, Inc.
THE WOODLANDS, TX, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted...
Captain T Cell Secures Seed Financing Round Totaling € 8.5 Million
May 22, 2024 04:00 ET
|
AKAMPION
i&i Biotech Fund I SCSp, Brandenburg Kapital GmbH and HIL-INVENT Ges.m.b.H. participated in the seed roundFunds will be used to accelerate a new generation of T cell therapies against solid tumors...
7 Hills Pharma Expands Pioneering Patent Portfolio With New Claims Covering Innovative Combination Therapies
June 09, 2022 19:53 ET
|
7 Hills Pharma
HOUSTON, June 09, 2022 (GLOBE NEWSWIRE) -- 7 Hills Pharma LLC (“7 Hills” or “7HP”) has secured newly issued US patent claims that significantly expand the extent of the company’s intellectual...
New Study Demonstrates Integrin Activation Can Bring the Heat to Cold Melanoma Tumors
May 18, 2022 19:23 ET
|
7 Hills Pharma
HOUSTON, May 18, 2022 (GLOBE NEWSWIRE) -- 7 Hills Pharma LLC (“7 Hills” or “7HP”), together with The University of Texas MD Anderson Cancer Center (“MD Anderson”) and Texas Heart Institute (“THI”),...
Genmab and Synaffix Enter into License Agreement for ADC Technology
January 04, 2022 09:00 ET
|
Genmab A/S
Media Release Synaffix to provide access to proprietary antibody-drug conjugate (ADC) technologiesGenmab secures rights for conducting research on ADCs against multiple drug targets with options for...